Skip to main content

Day: April 17, 2025

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors (the “Committee”) granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4). The Committee granted a non-qualified stock option to purchase 400,000 shares of the Company’s common stock to Lisa von Moltke, M.D., who was recently appointed to the role of Head of Research and Development...

Continue reading

Goosehead Insurance Appoints Bill Wade to Board of Directors

Wade Brings Proven Expertise in AI-Driven Innovation and Scalable Tech-Enabled Growth WESTLAKE, Texas, April 17, 2025 (GLOBE NEWSWIRE) — Goosehead Insurance (NASDAQ: GSHD), a leader in personal lines insurance distribution, is proud to announce the appointment of Bill Wade to its Board of Directors. Wade, with over 25 years of experience as a senior partner and consultant at Bain & Company, brings deep expertise in leveraging emerging technologies, particularly artificial intelligence (AI), to fuel innovation, operational efficiency, and transformational growth. Throughout his career, Wade has been at the forefront of integrating digital strategies to help companies and private equity firms optimize performance and achieve scalable, tech-enabled growth. His work includes implementing AI-powered analytics, driving digital transformation,...

Continue reading

FLUENT Reports Fourth Quarter and Full Year 2024 Results

– Annual Revenue Grew 6.4% Year-over-Year to Record $103.6 million – – Completed Transformative Acquisition of RIV Capital, Adding New York Retail, Wholesale and Cultivation Operations to Multi-State Footprint – – Successfully Closed Non-Dilutive Debt Refinancing at Favorable Interest Rate and Terms – – Ended Fiscal Year With More Than $40 Million of Cash and Cash Equivalents, Positioning Company For Additional Expansion and Growth – – Expanded Brand Presence Through Strategic Launches, including MOODs and KNACK in New York and Hyer Kind Concentrates in Florida – TAMPA, Fla., April 17, 2025 (GLOBE NEWSWIRE) — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a vertically-integrated, multi-state cannabis company, today announced...

Continue reading

Aja Health and Wellness Inc. Announces Resignation of Director

Not for dissemination in the United States of America VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) — Aja Health and Wellness Inc. (“Aja” or the “Company”) (TSXV:AJA) announces they have accepted the resignation of Alnesh Mohan as a director of the Company. “The board would like to thank Alnesh for his dedicated service and wish him well in his future endeavours,” said Sanjeev Parsad. On behalf of the Board of Directors “Sanjeev Parsad” Sanjeev ParsadPresident, CEO and Director Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, contact: Sanjeev Parsad, President and CEOPhone: (604) 678.9115Fax:...

Continue reading

Westhaven Files Technical Report in Support of Updated Preliminary Economic Assessment for the Shovelnose Gold Project, British Columbia

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V:WHN) (“Westhaven”) announces that it has filed an independent technical report pursuant to National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) supporting the Updated Preliminary Economic Assessment (the “Updated PEA”) for its 100% owned Shovelnose Gold Project, under the Westhaven profile on Sedar+ (www.sedarplus.com). The Company’s news release dated March 3, 2025 summarizes the positive results of the Updated PEA for the Shovelnose Gold Project, located within the prospective Spences Bridge Gold Belt, bordering the Coquihalla Highway approximately 30 kilometres south of Merritt, British Columbia. The Technical Report, titled “Updated Preliminary Economic Assessment and Mineral Resource Estimate...

Continue reading

Inventus Announces Early Warrant Exercise Incentive Program

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce that the Company will make an application to the TSX Venture Exchange (the “TSXV”) for approval of the implementation of an early warrant exercise incentive program (the “Program”) designed to encourage the early exercise of up to 15,000,000 outstanding common share purchase warrants (the “Eligible Warrants”) originally issued in connection with the Company’s private placement financing that closed on November 6th, 2024. Each Eligible Warrant entitles the holder to purchase one common share of the Company at a price of $0.09 per share and expires on November 6th, 2026. In order to encourage the early exercise of such Eligible Warrants, the Company will be seeking approval of the TSXV to an amendment...

Continue reading

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilities Formalized agreement aligns with previously announced topline forecastsWARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities. Tevogen Bio will provide the primary staff and operations for the facility, which is a key component of the company’s long-term strategy to accelerate development timelines, maintain operational agility, and control cost. Tevogen Bio believes that this agreement should allow the...

Continue reading

CHAGEE Rings the Opening Bell on The Nasdaq

Company Celebrates Transition to a Public Company; Shares Trade Under “CHA” Ticker NEW YORK and SHANGHAI, April 17, 2025 (GLOBE NEWSWIRE) — Chagee Holdings Limited (“CHAGEE”), a leading premium tea drinks brand unique in creating a tea beverage composed of extracted original tea leaves and dairy, rang the opening bell at The Nasdaq today, officially celebrating its transition to a public company. The company shares began trading today. Junjie Zhang, Founder, Chairman of the Board, and CEO; and Hongfei Huang (Aaron), CFO; were joined by partners and friends of the Company at The Nasdaq MarketSite. “Since founding CHAGEE in 2017, we envisioned creating a global brand,” said Junjie Zhang, Founder, Chairman of the Board, and CEO of CHAGEE. “This is just the beginning. We will continually support healthy lifestyle choices, drive industry...

Continue reading

AI TRANSPORTATION ACQUISITION CORP ANNOUNCES DELISTING FROM NASDAQ AND EXPECTED SEC DEREGISTRATION

New York, New York, April 17, 2025 (GLOBE NEWSWIRE) — AI Transportation Acquisition Corp (Nasdaq: AITR), a publicly-listed special purpose acquisition company (“AITR”), today announced that The Nasdaq Stock Market, LLC (“Nasdaq”) determined to suspend trading and delist AITR’s securities from Nasdaq due to AITR’s failure to pay certain fees required by Listing Rule 5250(f), unless AITR appeals this determination. AITR does not intend to request a hearing to appeal the determination, which decision was based on a careful review of numerous factors, including the potential for limiting the significant costs associated with remaining listed on Nasdaq and complying with Nasdaq listing standards. AITR’s securities includes its ordinary shares value $0.0001 per share (the “Ordinary Shares”), its publicly-traded...

Continue reading

Marie Brizard Wine & Spirits: 2024 full-year earnings

                Charenton-le-Pont, 17 April 2025                                                                2024 full-year earnings Initial results of the Group’s transformation plan and resilience of results despite continued slowdown in spirits marketEBITDA of €15.2m in 2024, i.e. 8.1% of net sales, compared with €13.3m in 2023 (6.9% of net sales). Net profit (Group share) of €9.6m in 2024, compared with €8.7m in 2023 From 2025, impact of sharply rising costs of matured spirits, which the Group will endeavour to mitigate through its pricing policy and productivity projectsNB: All revenue growth figures reported herein are at constant exchange rates and consolidation scope, unless stated otherwise Marie Brizard Wine & Spirits (Euronext: MBWS) today announces its consolidated earnings for the 2024 financial year as...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.